Hints and tips:
Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements
Pharma group plans to make mRNA-based inoculation in Germany and ship it worldwide
UK pharma group has teamed up with South Korea’s SK Bioscience on jab that uses its adjuvant technology
...As well as partnering with Bayer to produce its Covid vaccine, CureVac has an agreement with the British pharma company GlaxoSmithKline to create a next generation of jabs....
...Following a meeting with pharma executives at the White House in early March, German media reported that the Trump administration had sought to lure the company, which also has a Boston base, to the US and...
...Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs....
...When pharma companies were retrenching 10 years ago, he suspects early stage vaccine programmes were among those cut....
...Stefan Oelrich, the head of Bayer’s pharma division, said: “We are highly committed to making our capabilities and networks available to help end this pandemic.”...
...The UK-based pharma giant has been working with France’s Sanofi to develop a Covid-19 vaccine, and it has increased manufacturing capacity for its adjuvant, which can help give longer lasting immunity, in...
...Eisai alone has transferred licences for about 60 medicines to Germany — at a cost of about €7,200 each simply to change the name of the licence holder from “Eisai Europe in Hatfield” to “Eisai GmbH in Frankfurt...
...Dag Falk-Petersen, chief executive of Avinor, says there are incentives for airports to move quickly....
...In the US, Nestlé’s Galderma unit markets a rival, known as Dysport, while Germany's Merz pharma sells a neurotoxin under the Xeomin brand....
...The carbonated version of the drink familiar to western consumers was created through a joint venture between TC Pharma and an Austrian partner in 1987....
...Botox is the leading wrinkle smoother, with a global market share of roughly 85 per cent, although dermatologists say it still faces fierce competition from drugs such as Nestlé’s Dysport and Merz Pharma...
...The £376m acquisition of German rival PolymerLatex, completed in March, nearly doubled the size of the business, and, combined with the sale of the lower-margin, non-core pharma division in November, completed...
...Falk Frey, an analyst at Moody’s, said he expected strong demand from China and the US to drive global car sales up by more than 5 per cent to 76m vehicles this year....
...Nycomed, a privately held business with a presence in Russia and Brazil, will expand into China with the purchase of 51.3 per cent of Guangdong Techpool Bio-Pharma for $214m....
...But generics is not “big pharma”. Integrating a business with intense cost competition that often butts heads with the likes of Pfizer itself seems a taller order than just writing a big cheque....
...Operating margins of about 18 per cent are also below the 25 per cent typical of a speciality pharma company. So what does Abbott see in the business? Earnings, for one....
...Solvac, Solvay’s largest controlling shareholder that holds the Solvay family’s 30 per cent stake, is understood to have approved the sale of the pharma business, which began in April....
...The pharma business had revenue last year of €2.7bn, or 28 per cent of the company’s total sales of €9.49bn....
...Solvay retained a string of investment banks this year to explore options for the pharma division and attracted preliminary interest from several large pharmaceuticals companies before many dropped out....
International Edition